Replies to post #130426 on Biotech Values

[DewDiligence]

They [SNY] gain little other than a foothold for the AG to use when other generics reach market.

SNY gained something else from the AG launch: a defense other than price-cutting to NVS’ market-share gains in the hospital segment, which is for SNY to gain share in the retail segment. Without an AG, SNY couldn’t have done that.

I think we’re on the same wavelength here.